PT - JOURNAL ARTICLE AU - Qingrui Huang AU - Jiawei Zeng AU - Qingyun Lang AU - Feng Gao AU - Dejun Liu AU - Siyu Tian AU - Rui Shi AU - Ling Luo AU - Hao Wang AU - Liping Hu AU - Linrui Jiang AU - Yawei Liu AU - Kailiang Li AU - Yunbo Wu AU - Junjie Xu AU - Wenxi Jiang AU - Ning Guo AU - Zhihai Chen AU - Xiaohua Hao AU - Ronghua Jin AU - Jinghua Yan AU - Yufa Sun TI - Impact of various vaccine boosters on neutralization against Omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine AID - 10.1101/2022.01.25.476850 DP - 2022 Jan 01 TA - bioRxiv PG - 2022.01.25.476850 4099 - http://biorxiv.org/content/early/2022/01/27/2022.01.25.476850.short 4100 - http://biorxiv.org/content/early/2022/01/27/2022.01.25.476850.full AB - Since the first report on November 24, 2021, the Omicron SARS-CoV-2 variant is now overwhelmingly spreading across the world. Two SARS-CoV-2 inactivated vaccines (IAVs), one recombinant protein subunit vaccine (PRV), and one adenovirus-vectored vaccine (AdV) have been widely administrated in many countries including China to pursue herd immunity. Here we investigated cross-neutralizing activities in 341 human serum specimens elicited by full-course vaccinations with IAV, PRV and AdV, and by various vaccine boosters following prime IAV and AdV vaccinations. We found that all types of vaccines induced significantly lower neutralizing antibody titers against the Omicron variant than against the prototype strain. For prime vaccinations with IAV and AdV, heterologous boosters with AdV and PRV, respectively, elevated serum Omicron-neutralizing activities to the highest degrees. In a mouse model, we further demonstrated that among a series of variant-derived RBD-encoding mRNA vaccine boosters, it is only the Omicron booster that significantly enhanced Omicron neutralizing antibody titers compared with the prototype booster following a prime immunization with a prototype S-encoding mRNA vaccine candidate. In summary, our systematical investigations of various vaccine boosters inform potential booster administrations in the future to combat the Omicron variant.Competing Interest StatementThe Institute of Microbiology, Chinese Academy of Sciences (IMCAS) holds the patent on ZF2001 vaccine.